BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Helix Biopharma (CC:HBP) Announces Appointment of Director


6/14/2013 9:59:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

AURORA, ON--(Marketwired - June 13, 2013) - Helix BioPharma Corp. (TSX: HBP) (FRANKFURT: HBP), a biopharmaceutical company developing drug candidates for the prevention and treatment of cancer, today announced the appointment of Stace Wills to the board of directors. Mr. Wills is a resident Canadian and his appointment was effective June 12, 2013.

Commenting on the appointment, Mario Gobbo, Chairman of the Board of Helix, said, "Mr. Wills has over 20 years of experience in the life sciences, biotech and technology sectors and I look forward to the insights he will bring to our board and to working with him as Helix pursues its product development initiatives."

Helix also announced that Andrew J. MacDougall, who had agreed to serve on the board of directors on an interim basis pending the appointment of a resident Canadian director to satisfy the statutory requirement for resident Canadians to comprise at least 25% of Helix's board of directors, voluntarily resigned as a director following the appointment of Mr. Wills. Mr. Gobbo commented, "Mr. MacDougall's interim service on the board has provided us with time to complete our director recruitment process. We thank him for his contributions as a director and look forward to his continued service as counsel to the company."

Following the appointment of Mr. Wills and the resignation of Mr. MacDougall, the board is comprised of six directors, five of whom are independent of Helix.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".


Investor Relations:
Helix BioPharma Corp.
Tel: 905 841-2300
Email: ir@helixbiopharma.com



Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES